1. Effects of dapagliflozin on cardiovascular and kidney events by baseline eGFR and UACR in patients with type 2 diabetes mellitus: a patient-level pooled analysis of DECLARE-TIMI 58 and DAPA-CKD trials. (3rd October 2022) Authors: Moura, F; Wiviott, S; Chertow, G; Dwyer, J; Gause-Nilsson, I; Johansson, P; Langkilde, A; McMurray, J; Mosenzon, O; Raz, I; Rossing, P; Wheeler, D; Sabatine, M; Heerspink, H Journal: European heart journal Issue: Volume 43(2022)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Influence of cardiovascular drugs on the efficacy and safety of dapagliflozin in patients with type 2 diabetes mellitus in the DECLARE-TIMI 58 trial. (14th October 2021) Authors: Oyama, K; Raz, I; Cahn, A; Goodrich, E; Bhatt, D; Leiter, L; McGuire, D; Wilding, J; Gause-Nilsson, I; Mosenzon, O; Sabatine, M; Wiviott, S Journal: European heart journal Issue: Volume 42(2021)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗